Avanos Medical (NYSE:AVNS) Sets New 12-Month High - Here's Why

Key Points

• Shares hit a new 52-week high, trading as high as $24.58 (last $24.545) on heavy volume of ~12.3M shares and were up 69.2% from the prior close of $14.53.
• Quarterly results beat estimates—Avanos reported $0.29 EPS vs. $0.24 expected and $180.9M revenue vs. $174.7M expected, and it set FY2026 guidance of $0.90–$1.10 EPS.
• Institutional interest is very high (institutions own ~95.17% of shares) with major additions such as Northwestern Mutual buying ~14.9M shares, while analyst views remain mixed and the consensus rating is "Reduce".

Avanos Medical, Inc. (NYSE:AVNS - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $24.58 and last traded at $24.5450, with a volume of 12314663 shares traded. The stock had previously closed at $14.53.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AVNS. Wall Street Zen upgraded Avanos Medical from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Avanos Medical in a research report on Monday, December 22nd. Finally, Zacks Research upgraded Avanos Medical from a "strong sell" rating to a "hold" rating in a research report on Monday, January 26th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Reduce".

Avanos Medical Trading Up 69.2%

The stock has a market cap of $1.14 billion, a PE ratio of -15.56 and a beta of 1.05. The business has a 50-day moving average of $14.05 and a 200 day moving average of $12.52. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15.

Avanos Medical (NYSE:AVNS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of $0.24 by $0.05. The firm had revenue of $180.90 million during the quarter, compared to analysts' expectations of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The firm's quarterly revenue was up .7% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 EPS. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. Equities research analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Institutional Trading of Avanos Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. grew its holdings in Avanos Medical by 1,596,514.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company's stock valued at $167,287,000 after buying an additional 14,895,480 shares during the period. Armistice Capital LLC grew its holdings in Avanos Medical by 28.0% in the 4th quarter. Armistice Capital LLC now owns 3,200,000 shares of the company's stock valued at $35,936,000 after buying an additional 700,000 shares during the period. State Street Corp grew its holdings in Avanos Medical by 2.8% in the 4th quarter. State Street Corp now owns 1,954,785 shares of the company's stock valued at $21,952,000 after buying an additional 53,523 shares during the period. Geode Capital Management LLC grew its holdings in Avanos Medical by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,084,504 shares of the company's stock valued at $12,180,000 after buying an additional 16,980 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Avanos Medical by 20.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,040,666 shares of the company's stock valued at $11,687,000 after buying an additional 176,716 shares during the period. Hedge funds and other institutional investors own 95.17% of the company's stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.